Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have ...

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.

Merck & Co. Inc. closed 36.67% below its 52-week high of $128.73, which the company reached on July 26th.

Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

The president has fired or demoted over 20 inspectors general since he took office. Employees say they are demoralized and ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best ...